1,174
edits
ACST-1: Difference between revisions
Jump to navigation
Jump to search
→Major Points
Tag: visualeditor |
Tag: visualeditor |
||
| Line 7: | Line 7: | ||
==Major Points== | ==Major Points== | ||
The stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1) randomized 3,120 patients to | The stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1) randomized 3,120 patients to assess the effect of immediate CEA on stroke risk as compared to deferred CEA. | ||
Successful immediate CEA for asymptomatic patients <75 years of age at entry of trial reduces 10-year risk of stroke.<!-- Now write a succinct paragraph or two describing the major points in the article. Again, ACCORD's major points: --> | |||
==Guidelines== | ==Guidelines== | ||
| Line 125: | Line 127: | ||
===Subgroup Analysis<!-- Was there a subgroup analysis? If so, include a summary of it here. -->=== | ===Subgroup Analysis<!-- Was there a subgroup analysis? If so, include a summary of it here. -->=== | ||
* At 10-years, there was no significant heterogeneity between benefits in subgroups of | * At 10-years, the benefits of CEA was not significant for both men and for women ≥75 years old at entry to trial | ||
* At 10-years, there was no significant heterogeneity between benefits in subgroups of gender, pre-randomisation cholesterol, pre-randomisation systolic blood pressure, severity of stenosis, diabetes mellitus, IHD, use of anti-hypertensive, anti-thrombotic or lipid-lowering agents at entry. | |||
* At 10-years, there was no significant heterogeneity between perioperative hazards in subgroups of age, gender or severity of stenosis. | * At 10-years, there was no significant heterogeneity between perioperative hazards in subgroups of age, gender or severity of stenosis. | ||
* However subgroup analyses are not definitive due to the small number of events in the trial.<!-- Were there significant adverse events recorded other than those listed in the secondary outcomes? If so, list them here --> | * However subgroup analyses are not definitive due to the small number of events in the trial.<!-- Were there significant adverse events recorded other than those listed in the secondary outcomes? If so, list them here --> | ||